title: Photodynamic therapy for choroidal metastasis in 8 cases.
abstract: OBJECTIVE
  To determine the efficacy of photodynamic therapy (PDT) in the treatment of choroidal metastasis.
  
  
  METHODS
  Retrospective, interventional case series.
  
  
  METHODS
  Nine tumors in 8 eyes of 8 patients.
  
  
  METHODS
  Photodynamic therapy using verteporfin at a dose of 6 mg/m(2) body surface area and 689 nm diode laser at an intensity of 600 mW/cm(2) for 83 seconds (50 J/cm(2)).
  
  
  METHODS
  Tumor control and best-corrected visual acuity.
  
  
  RESULTS
  Nine choroidal metastases in 8 eyes were treated with 1 (8 tumors) or 2 (1 tumor) sessions of PDT. The mean tumor basal diameter was 7 mm (median, 7 mm [range, 2-13 mm]), and mean tumor thickness was 2.9 mm (median, 2.9 mm [range, 1.6-4 mm]). All 9 tumors were associated with shallow subretinal fluid. After PDT, complete control with resolution of subretinal fluid was achieved in 7 tumors (78%), with mean tumor thickness reduction of 39% (median, 43% [range, 6%-61%]). Two tumors failed to respond to PDT, both requiring plaque radiotherapy. Improvement or stabilization of vision was achieved in 7 eyes. Photodynamic therapy-related complications included intraretinal hemorrhage in 1 eye.
  
  
  CONCLUSIONS
  Photodynamic therapy can be an effective alternative for the treatment of choroidal metastasis.
  
  
  BACKGROUND
  The author(s) have no proprietary or commercial interest in any materials discussed in this article.
authors.affiliation: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Swathi
authors.initials: S
authors.lastname: Kaliki
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
authors.forename: Saad A
authors.initials: SA
authors.lastname: Al-Dahmash
authors.forename: Arman
authors.initials: A
authors.lastname: Mashayekhi
authors.forename: Jerry A
authors.initials: JA
authors.lastname: Shields
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D002830:Choroid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D058471:Subretinal Fluid; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014463:Ultrasonography; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin